Form 4: Revolution Medicines Director Barbara Weber Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Barbara Weber of Revolution Medicines, Inc. executed a sale of common stock on October 8, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On October 8, 2024, Barbara Weber, a director of Revolution Medicines, Inc., sold 5,200 shares of common stock.
- The sale was executed at a weighted average price of $48.0224 per share, with individual trades ranging from $48.00 to $48.08.
- The transaction was conducted under a 10b5-1 trading plan adopted on May 29, 2024.
- Following the transaction, Weber directly owns 13,065 shares, which includes 4,248 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a routine disclosure of a pre-planned stock sale. It doesn't inherently indicate positive or negative news about the company.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives and directors to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| May 29, 2024 | Date the Reporting Person adopted the 10b5-1 trading plan |
| October 08, 2024 | Date of the transaction (sale of common stock) |
| October 10, 2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.